Rubius Therapeutics, Inc. (NASDAQ:RUBY - Get Rating) - Research analysts at SVB Leerink lifted their Q3 2022 EPS estimates for shares of Rubius Therapeutics in a report released on Tuesday, May 10th. SVB Leerink analyst J. Chang now expects that the company will post earnings of ($0.49) per share for the quarter, up from their prior forecast of ($0.50). SVB Leerink has a "Market Perform" rating and a $3.00 price objective on the stock. SVB Leerink also issued estimates for Rubius Therapeutics' Q4 2022 earnings at ($0.25) EPS, FY2022 earnings at ($1.66) EPS and FY2023 earnings at ($0.72) EPS. Rubius Therapeutics (NASDAQ:RUBY - Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.01). During the same period last year, the company earned ($0.51) EPS.
Several other research firms have also recently weighed in on RUBY. Morgan Stanley cut their price objective on shares of Rubius Therapeutics from $15.00 to $4.00 and set an "equal weight" rating for the company in a research report on Monday, April 11th. HC Wainwright lowered their target price on Rubius Therapeutics from $15.00 to $8.00 in a research note on Wednesday. Guggenheim lowered their target price on Rubius Therapeutics from $25.00 to $5.00 and set a "buy" rating for the company in a research note on Monday, April 11th. Finally, Zacks Investment Research downgraded Rubius Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, February 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $6.20.
RUBY opened at $1.24 on Friday. Rubius Therapeutics has a twelve month low of $1.18 and a twelve month high of $29.06. The company has a 50-day simple moving average of $3.62 and a 200 day simple moving average of $7.87. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.43.
Several institutional investors have recently added to or reduced their stakes in the company. Baillie Gifford & Co. increased its stake in shares of Rubius Therapeutics by 5.0% in the fourth quarter. Baillie Gifford & Co. now owns 4,930,859 shares of the company's stock valued at $47,730,000 after buying an additional 237,027 shares during the period. BlackRock Inc. increased its stake in shares of Rubius Therapeutics by 0.7% in the first quarter. BlackRock Inc. now owns 3,506,569 shares of the company's stock valued at $19,318,000 after buying an additional 24,768 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Rubius Therapeutics by 28.9% in the fourth quarter. JPMorgan Chase & Co. now owns 3,161,516 shares of the company's stock valued at $30,602,000 after buying an additional 708,647 shares during the period. Victory Capital Management Inc. boosted its holdings in Rubius Therapeutics by 20.0% in the first quarter. Victory Capital Management Inc. now owns 2,932,248 shares of the company's stock valued at $16,157,000 after acquiring an additional 489,248 shares during the last quarter. Finally, Capital World Investors boosted its holdings in Rubius Therapeutics by 3.8% in the fourth quarter. Capital World Investors now owns 2,751,000 shares of the company's stock valued at $26,630,000 after acquiring an additional 100,000 shares during the last quarter. 98.93% of the stock is owned by institutional investors.
In other news, Director David R. Epstein acquired 30,000 shares of the stock in a transaction dated Thursday, April 21st. The stock was bought at an average price of $1.44 per share, with a total value of $43,200.00. Following the completion of the purchase, the director now directly owns 4,720,012 shares of the company's stock, valued at approximately $6,796,817.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 52.60% of the stock is currently owned by insiders.
Rubius Therapeutics Company Profile (Get Rating)
Rubius Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Rubius Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rubius Therapeutics wasn't on the list.
While Rubius Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here